Biofrontera (BFRI) EPS (Diluted) Growth (1y) (2022 - 2026)
Biofrontera (BFRI) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -304.28% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 1.28% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -15.70% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 13.47% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 30.20% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 385.28% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Biofrontera | 19.06 Mn | 14.35 Mn | 9.59 Mn | 91.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.79% |
| Dec 31, 2025 | 405.81% |
| Sep 30, 2025 | 37.16% |
| Jun 30, 2025 | -1,027.86% |
| Mar 31, 2025 | 83.56% |
| Dec 31, 2024 | -111.10% |
| Sep 30, 2024 | 78.84% |
| Jun 30, 2024 | 99.30% |
| Mar 31, 2024 | 48.58% |
| Dec 31, 2023 | 186.54% |
| Sep 30, 2023 | -105.47% |
| Jun 30, 2023 | -700.46% |
| Mar 31, 2023 | -186.29% |
| Dec 31, 2022 | 92.73% |
| Sep 30, 2022 | 94.36% |
| Jun 30, 2022 | 90.13% |
| Mar 31, 2022 | 173.47% |